Polaryx Therapeutics, Inc. (PLYX) Form 8-K Material Events
Polaryx Therapeutics, Inc. (PLYX) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: PLYX
CIK: 2075320
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: WY
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Grant Thornton LLP
Auditor SinceSince 12/31/2024 12:00:00 AM
Lead Engagement PartnerBryan Merrigan
Audit LocationEdison, New Jersey, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-09-14 | 2026-09-10 | CURRENT REPORT | 0001213900-26-099416 | View SEC Doc Filr Page |
| 8-K | 2026-09-01 | 2026-09-01 | CURRENT REPORT | 0001213900-26-096235 | View SEC Doc Filr Page |
| 10-Q | 2026-08-13 | 2026-06-30 | QUARTERLY REPORT | 0001213900-26-089118 | View SEC Doc Filr Page |
| ARS | 2026-07-28 | 2025-12-31 | ARS | 0001213900-26-082353 | View SEC Doc Filr Page |
| DEFA14A | 2026-07-28 | — | DEFINITIVE ADDITIONAL MATERIALS | 0001213900-26-082345 | View SEC Doc Filr Page |
| DEF 14A | 2026-07-28 | 2026-09-10 | PROXY STATEMENT | 0001213900-26-082339 | View SEC Doc Filr Page |
| S-8 | 2026-07-24 | — | REGISTRATION STATEMENT | 0001213900-26-081404 | View SEC Doc Filr Page |
| 8-K | 2026-07-21 | 2026-07-19 | CURRENT REPORT | 0001213900-26-080041 | View SEC Doc Filr Page |
| 8-K | 2026-07-17 | 2026-07-16 | CURRENT REPORT | 0001213900-26-078912 | View SEC Doc Filr Page |
| 4 | 2026-05-28 | 2026-05-27 | 4 Filing | 0001213900-26-062322 | View SEC Doc Filr Page |
| 8-K | 2026-05-28 | 2026-05-27 | CURRENT REPORT | 0001213900-26-062155 | View SEC Doc Filr Page |
| 10-Q | 2026-05-15 | 2026-03-31 | QUARTERLY REPORT | 0001213900-26-056973 | View SEC Doc Filr Page |
| 10-K | 2026-03-24 | 2025-12-31 | ANNUAL REPORT | 0001213900-26-033064 | View SEC Doc Filr Page |
| 4 | 2026-02-20 | 2026-02-18 | 4 Filing | 0001213900-26-018845 | View SEC Doc Filr Page |
| SCHEDULE 13D | 2026-02-05 | — | SCHEDULE 13D Filing | 0001213900-26-012759 | View SEC Doc Filr Page |
| 424B4 | 2026-02-02 | — | PROSPECTUS | 0001213900-26-010761 | View SEC Doc Filr Page |
| EFFECT | 2026-01-29 | — | EFFECT Filing | 9999999995-26-000339 | View SEC Doc Filr Page |
| 3 | 2026-01-29 | 2026-01-29 | OWNERSHIP DOCUMENT | 0001213900-26-009664 | View SEC Doc Filr Page |
| 3 | 2026-01-29 | 2026-01-29 | OWNERSHIP DOCUMENT | 0001213900-26-009569 | View SEC Doc Filr Page |
| 3 | 2026-01-29 | 2026-01-29 | OWNERSHIP DOCUMENT | 0001213900-26-009567 | View SEC Doc Filr Page |
| 3 | 2026-01-29 | 2026-01-29 | OWNERSHIP DOCUMENT | 0001213900-26-009566 | View SEC Doc Filr Page |
| 3 | 2026-01-29 | 2026-01-29 | OWNERSHIP DOCUMENT | 0001213900-26-009565 | View SEC Doc Filr Page |
| 3 | 2026-01-29 | 2026-01-29 | OWNERSHIP DOCUMENT | 0001213900-26-009564 | View SEC Doc Filr Page |
| 3 | 2026-01-29 | 2026-01-29 | OWNERSHIP DOCUMENT | 0001213900-26-009563 | View SEC Doc Filr Page |
| CERT | 2026-01-28 | — | CERT Filing | 0001354457-26-000098 | View SEC Doc Filr Page |